TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: In-office Placement of the Propel Mini Sinus Implant in the Frontal Sinus Ostia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Patient has provided written informed consent using a form approved by the reviewing IRB.~* Patient is 18 years of age or older.~* Patient is willing and able to comply with protocol requirements.~* Patient has CRS defined as sinonasal inflammation persisting for more than 12 weeks and complains of at least 2 of the 4 following symptoms: nasal blockage/obstruction/congestion, nasal blockage/obstruction/congestion, nasal discharge (anterior/posterior), facial pain/pressure, reduction/loss of smell~* CRS diagnosis confirmed by CT scan within 3 months prior to enrollment~* Bilateral frontal sinusitis confirmed by Lund-Mackay score of ≥1 on each side~* Post-endoscopic sinus surgery, patient has bilateral obstruction of the frontal sinus ostia by scarring and/or polypoid edema.~* Patient is a candidate for an in-office balloon dilation procedure.~* In the opinion of the investigator, treatment with the Propel Mini Sinus Implant as an adjunct to balloon sinus dilation is technically feasible and clinically indicated in the frontal sinus ostia.~Exclusion Criteria:~* Expanded amount of ethmoid sinonasal polyps extending beyond the middle meatus of grade 3 or 4 unless reduced prior to randomization in the study.~* Oral-steroid dependent condition such as chronic obstructive pulmonary disease (COPD) or other conditions.~* Known history of allergy or intolerance to corticosteroids or mometasone furoate.~* Clinical evidence of acute bacterial sinusitis or invasive fungal sinusitis.~* Active viral illness (e.g., flu, shingles).~* Clinical evidence of disease or condition expected to compromise survival or ability to complete follow-up assessments through Day 180 post-procedure.~* Currently participating in another clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PROPEL Mini Sinus Implant (Type: EXPERIMENTAL): Placement of the Propel Mini Sinus Implant in one frontal sinus ostia (FSO) assigned to the treatment group following in-office balloon dilation
- Balloon Sinus Dilation Alone (Type: ACTIVE_COMPARATOR): In-office balloon dilation of the contralateral frontal sinus ostia (FSO) without implant placement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Pomegranate Extract on Intestinal Flora

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 20-50 years of age at screen.~2. In good health~3. Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent.~Exclusion Criteria:~1. Any history of gastrointestinal disease except for appendectomy~2. Any use of antibiotics or laxatives during the 2 months prior to study enrollment.~3. Any subject with a history of diabetes mellitus, or other serious medical condition, such as chronic hepatic or renal disease, bleeding disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as systolic BP\>160mmHg, diastolic BP\>95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history or routine physical examination.~4. Any subject consuming pre- or probiotics~5. Any subject with a screening laboratory value outside of the laboratory normal range that is considered clinically significant for study participation by the investigator.~6. Any subject who currently uses tobacco products or has used tobacco products within the last year.~7. Any subject who is unable or unwilling to comply with the study protocol.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- urolithin excretors (Type: ACTIVE_COMPARATOR): The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
- non excretors (Type: ACTIVE_COMPARATOR): The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Brief Community Linkage Intervention for Dually Diagnosed Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients over 18 years old.~2. Patients who have a substance abuse disorder and a diagnosis of schizophrenia, schizoaffective disorder, or bipolar I disorder.~3. Patients seeking outpatient treatment for the above disorders from the VA.~4. Physically mobile~5. Agree to take public transportation if they do not have other private sources.~Exclusion Criteria:~1. Patients who only have either a mental health problem, or a substance abuse problem, but not both.~2. Patients who do not have a residence where they can stay upon discharge from the hospital.~3. Patients who are not sufficiently medically or psychiatrically stable to participate in residential or outpatient treatment. Those patients could be re-evaluated for the study once stabilized.~4. Patients exclusively engaged in methadone maintenance programs.~5. Patients who represent a serious suicide risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
- Arm 2 (Type: ACTIVE_COMPARATOR): This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female older than 17 years.~2. Clinical diagnosis of probable multiple system atrophy~3. Provide written informed consent to participate in the study~4. Understand that they may withdraw their consent at any time~Exclusion Criteria:~1. Women who are pregnant or lactating~2. In the investigator's opinion, have any other significant systemic, hepatic, cardiac or renal illness.~3. In the investigator's opinion, the subjects are significantly dehydrated, as determined by clinical evaluation including measurement of skin turgor, blood urea nitrogen and creatinine values.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Interventions included monthly infusions of intravenous immunoglobulin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mild, Moderate and Severe Renal Impairment Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2.~* Subject with renal impairment, as determined at Screening, with creatinine clearance as calculated by the Cockcroft-Gault formula of 60 to \< 90 mL/min (mild impairment), 30 to \< 60 mL/min (moderate impairment), or 15 to \< 30 mL/min (severe impairment), or a matched control subject (by age and body mass index) with a creatinine clearance of ≥ 90 mL/min.~* Subject has a Screening serum urate level ≥ 4.5 mg/dL and ≤ 10 mg/dL~Exclusion Criteria:~* Subject has a history or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological, or psychiatric disorders.~* Subject has a history or suspicion of kidney stones.~* Subject has a history of asthma.~* Subject has undergone major surgery within 3 months prior to Day 1.~* Subject has donated blood or experienced significant blood loss (\> 450 mL) within 12 weeks prior to Day 1 or gave a plasma donation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Mild renal impairment (Type: EXPERIMENTAL): RDEA3170 15 mg once daily fasted
- Cohort 2: Moderate renal impairment (Type: EXPERIMENTAL): RDEA3170 15 mg once daily fasted
- Cohort 3: Severe renal impairment (Type: EXPERIMENTAL): RDEA3170 15 mg once daily fasted
- Cohort 4: Control subjects with normal renal function (Type: EXPERIMENTAL): RDEA3170 15 mg once daily fasted

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and females~* Between 18 and 25 years of age~* First Episode Psychosis~* Attending ORYGEN Youth Health, a geographical based catchment area service for young people aged between 15 and 25.~Exclusion Criteria:~* Organic disorders presenting with a psychotic syndrome (e.g. brain tumour, temporal lobe epilepsy, HIV encephalopathy)~* Mental retardation (unable and/or unlikely to give appropriate information of symptomatology or side-effects (IQ approximately lower than 80)~* History of clinically significant physical illness (e.g. terminal cancer, renal dialysis)~* History of brain surgery~* History of brain infarction~* Pregnant or lactating women or women of childbearing potential not using an acceptable method of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Placebo pill (Type: PLACEBO_COMPARATOR): 4 placebo pills daily for 3 months
- Taurine 4g (Type: EXPERIMENTAL): Taurine 4g daily comprising four 1g pills

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with mixed dyslipidemia~Exclusion Criteria:~* Subjects with unstable medical conditions or medical conditions considered inappropriate in a clinical trial.~* Patients who are taking certain medications or unstable dose of specific medications.~* Women who are pregnant or plan on becoming pregnant or women who are lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): ABT-335 + 10 mg rosuvastatin
- B (Type: ACTIVE_COMPARATOR): ABT-335 + 20 mg rosuvastatin
- C (Type: PLACEBO_COMPARATOR): ABT-335 monotherapy
- D (Type: PLACEBO_COMPARATOR): 10 mg rosuvastatin monotherapy
- E (Type: PLACEBO_COMPARATOR): 20 mg rosuvastatin monotherapy
- F (Type: PLACEBO_COMPARATOR): 40 mg rosuvastatin monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants under 48 hours of age born at San Lucas Hospital during study enrollment period~* Infants with gestational age of \> 37 weeks as assessed by neonatologist~* Mother/guardian gives informed consent~* Infant is expected to reside in Puerto Rico for the following 8 months~Exclusion Criteria:~* Mother/guardian does not speak English or Spanish~* Mother/guardian has religious/philosophical objection to immunizations~* Infant has serious chronic or acute health problems that require hospitalization immediately (within 1 day) after birth (assessed by infant not being placed in San Lucas Hospital well-baby clinic)~* Mother expects to travel with infant during study period to a country known to have circulating poliovirus or that uses oral poliovirus vaccine (OPV)

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 48 Hours
- Healthy Volunteers: t

Study Arms:
- Cohort A-WHO/EPI Schedule (Type: EXPERIMENTAL): Received IPV at ages 6, 10, and 14 weeks (this schedule is also approved for use in the United States if an accelerated schedule is needed.
- Cohort A-US Schedule (Type: ACTIVE_COMPARATOR): Received IPV at ages 8, 16, and 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Integrated Care & Patient Navigators for Latinos With Serious Mental Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Identify ethnicity as Hispanic/Latino~* Identify with experience with a mental illness~Exclusion Criteria:~* Must be 18 years or older~* Have case manager they met on a regular basis (every week for the past 4 months) for physical health

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peer Navigator Intervention (Type: EXPERIMENTAL): Integrated care with a peer navigator to be provided for one year, where data will be collected at baseline, 4, 8 and 12 months.
- Controlled (Type: NO_INTERVENTION): Integrated care without a peer navigator, where data will be collected at baseline, 4, 8 and 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methadone Versus Morphine for Orthopedic Surgery Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-III~* Ages 18-65 years~* Presenting for lower extremity orthopedic surgery involving fracture of long bones at University of Louisville Hospital~* Surgery expected to last more than one hour~* Patient expected to have moderate to severe post-operative pain~* Patient refused regional anesthesia or has a contraindication to regional anesthesia~Exclusion Criteria:~* Any known contraindications to methadone including hypothyroidism, Addison's disease, prostatic hypertrophy, or urethral stricture.~* Difficulty or inability to understand the study or protocol~* Known renal or hepatic dysfunction~* BMI\> 35~* Known respiratory or cardiovascular problems, such as obstructive sleep apnea or oxygen saturation of less than 92% on room air~* Taking any of the known drugs that induce or inhibit the cytochrome p450 enzyme systems. Common examples of these drugs are antifungal, antiretroviral, barbiturates, dexamethasone, and macrolide antibiotics.~* Pregnancy~* Taking preoperative opioids for more than 2 weeks before the surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Methadone (Type: EXPERIMENTAL): Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine and 0.2 mg/kg of methadone IV with induction of general anesthesia.
- Control (Type: ACTIVE_COMPARATOR): Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine, and 0.2 mg/kg morphine (standard of care)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~A subject must meet all of the following criteria to be eligible for this study.~1. The subject and/or their parent/legal guardian are willing and able to provide signed informed consent.~2. The subject has successfully completed 28 weeks of treatment in Study 4658-US-201.~3. The subject has a parent(s) or legal guardian(s) who is able to understand and comply with all of the study procedure requirements.~Exclusion Criteria:~A subject who meets any of the following criteria will be excluded from this study.~1. The subject has a prior or ongoing medical condition that, in the Investigator's opinion, could adversely affect the safety of the subject or make it unlikely that the course of treatment or follow-up would be completed or impair the assessment of study results.

- Gender: MALE
- Minimum Age: 7 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- AVI-4658 (Eteplirsen) (Type: EXPERIMENTAL): Multiple-Dose Extension Study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Histologically or cytologically confirmed diagnosis of squamous cell or poorly differentiated carcinomas of the head and neck or lymphoepithelioma~* No prior chemotherapy or radiotherapy~* Prior surgical therapy will consist only of incisional or excisional biopsy, and organ sparing procedures such as debulking of airway-compromising tumors or neck dissection in a patient with an existing primary tumor~* Karnofsky performance status of \>= 70%~* Intact organ and bone marrow function~* Obtained informed consent~Exclusion Criteria:~* Demonstration of metastatic disease (i.e. M1 disease).~* Patients with a history of severe allergic reaction to docetaxel or other drugs formulated with polysorbate 80. History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, 5-fluorouracil, or hydroxyurea.~* Other coexisting malignancies or malignancies diagnosed within the previous 3 years with the exception of basal cell carcinoma, cervical cancer in situ, and other treated malignancies with no evidence of disease for at least 3 years.~* Prior surgical therapy other than incisional or excisional biopsy and organ-sparing procedures such as debulking of airway-compromising tumors or neck dissection in a patient with an unknown primary tumor. Any non-biopsy procedure must have taken place less than 3 months from initiating protocol treatment.~* Incomplete healing from previous surgery~* Pregnancy or breast feeding (men and women of child-bearing potential are eligible but must consent to using effective contraception during therapy and for at least 3 months after completing therapy)~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Patients with clinically significant pulmonary dysfunction, cardiomyopathy, or any history of clinically significant CHF are excluded. The exclusion of patients with active coronary artery disease will be at the discretion of the attending physician.~* Uncontrolled active infection unless curable with treatment of their cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Advanced Head and Neck Cancer (Type: EXPERIMENTAL): Patients with stage IVA and IVB or high-risk stage III squamous cell carcinomas of the head and neck

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete